Comparing IRIDEX (NASDAQ:IRIX) and Zynex (NASDAQ:ZYXI)

Zynex (NASDAQ:ZYXI – Get Free Report) and IRIDEX (NASDAQ:IRIX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

29.7% of Zynex shares are held by institutional investors. Comparatively, 20.1% of IRIDEX shares are held by institutional investors. 49.3% of Zynex shares are held by insiders. Comparatively, 8.6% of IRIDEX shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Zynex and IRIDEX”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zynex $108.20 million 0.04 $2.99 million ($2.43) -0.05
IRIDEX $52.67 million 0.16 -$4.44 million ($0.19) -2.45

Zynex has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zynex and IRIDEX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zynex -68.35% -804.30% -36.67%
IRIDEX -6.85% N/A -11.85%

Risk and Volatility

Zynex has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, IRIDEX has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zynex and IRIDEX, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zynex 1 0 0 0 1.00
IRIDEX 1 0 1 0 2.00

IRIDEX has a consensus price target of $3.00, indicating a potential upside of 543.36%. Given IRIDEX’s stronger consensus rating and higher probable upside, analysts plainly believe IRIDEX is more favorable than Zynex.

Summary

IRIDEX beats Zynex on 8 of the 13 factors compared between the two stocks.

About Zynex

(Get Free Report)

Zynex, Inc. develops, manufactures and markets medical devices used in pain management, rehabilitation and neurological diagnostics. The company’s products include electrical stimulation devices designed to support pain relief and muscle rehabilitation, as well as equipment used to assess neurological and muscle function. Zynex also provides related supplies and services for its devices. Its products are marketed primarily in the United States, with sales in some international markets. Founded in 1996, Zynex is headquartered in Englewood, Colorado.

About IRIDEX

(Get Free Report)

IRIDEX Corporation develops, manufactures and markets laser-based medical systems and related delivery devices for eye-care professionals. Its products are used to treat retinal diseases and glaucoma, including through laser procedures designed to preserve or improve vision. The company’s offerings include ophthalmic laser systems such as the Cyclo G6 glaucoma laser system and IQ-series photocoagulators, along with treatment-delivery devices and technologies including MicroPulse laser therapy. IRIDEX was founded in 1989 and serves customers internationally through direct sales and distribution partners.

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.